Partnership between academia and industry for drug discovery in Alzheimer's disease.


Journal Article

Drug discovery has traditionally been almost exclusively the purview of pharmaceutical and biotechnology companies, whereas universities have focused on basic research. However, given the challenges involved in discovering and developing truly effective, symptomatic treatments and disease-modifying drugs for Alzheimer's disease, there is a need to reassess this simple division of labor. Whereas each sector is likely to retain a core interest and expertise at either end of the drug discovery spectrum, there is room for closer cooperation at the intersection of the for-profit and not-for-profit sectors. The Alzheimer's Association Research Roundtable convened a meeting of senior industry researchers and academic investigators to discuss this intersection and to assess the opportunity for closer partnership on Alzheimer's disease drug discovery and development.

Full Text

Cited Authors

  • Ivinson, AJ; Lane, R; May, PC; Hosford, DA; Carrillo, MC; Siemers, ER

Published Date

  • March 2008

Published In

Volume / Issue

  • 4 / 2

Start / End Page

  • 80 - 88

PubMed ID

  • 18631952

Pubmed Central ID

  • 18631952

Electronic International Standard Serial Number (EISSN)

  • 1552-5279

International Standard Serial Number (ISSN)

  • 1552-5260

Digital Object Identifier (DOI)

  • 10.1016/j.jalz.2008.02.004


  • eng